tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

NMRA Stock Latest News

LB Pharmaceuticals appoints Kaya Pai Panandiker as CCO
The FlyLB Pharmaceuticals appoints Kaya Pai Panandiker as CCO
2d ago
LBRX
NMRA
Neumora Therapeutics Reports Q3 2025 Progress and Financials
PremiumCompany Announcements
Neumora Therapeutics Reports Q3 2025 Progress and Financials
2d ago
NMRA
Neumora Therapeutics, Inc.: Promising Growth and Innovation with Key Developments in Alzheimer’s Treatment
PremiumRatings
Neumora Therapeutics, Inc.: Promising Growth and Innovation with Key Developments in Alzheimer’s Treatment
8d ago
NMRA
Neumora Therapeutics reports Q3 EPS (35c), consensus (34c)
PremiumThe Fly
Neumora Therapeutics reports Q3 EPS (35c), consensus (34c)
8d ago
NMRA
Neumora Therapeutics price target raised to $8 from $6 at Needham
PremiumThe Fly
Neumora Therapeutics price target raised to $8 from $6 at Needham
17d ago
NMRA
Neumora Therapeutics’ Phase 3 Study on NMRA-335140: A Potential Game-Changer for Depression Treatment
PremiumCompany AnnouncementsNeumora Therapeutics’ Phase 3 Study on NMRA-335140: A Potential Game-Changer for Depression Treatment
17d ago
NMRA
Neumora Therapeutics Advances MDD Treatment with Long-term Study
Premium
Company Announcements
Neumora Therapeutics Advances MDD Treatment with Long-term Study
17d ago
NMRA
Neumora Therapeutics’ Phase 3 Study on NMRA-335140: A Potential Breakthrough for Major Depressive Disorder
Premium
Company Announcements
Neumora Therapeutics’ Phase 3 Study on NMRA-335140: A Potential Breakthrough for Major Depressive Disorder
17d ago
NMRA
Neumora Therapeutics’ NMRA-323511 Study: A Potential Breakthrough in Alzheimer’s Treatment
PremiumCompany Announcements
Neumora Therapeutics’ NMRA-323511 Study: A Potential Breakthrough in Alzheimer’s Treatment
17d ago
NMRA
Neumora Therapeutics upgraded to Buy from Neutral at Guggenheim
PremiumThe Fly
Neumora Therapeutics upgraded to Buy from Neutral at Guggenheim
18d ago
NMRA
Promising Preclinical Data and Strategic Focus Support Buy Rating for Neumora Therapeutics
PremiumRatings
Promising Preclinical Data and Strategic Focus Support Buy Rating for Neumora Therapeutics
18d ago
NMRA
Neumora Therapeutics Begins Phase 1 Study for NMRA-898
PremiumCompany Announcements
Neumora Therapeutics Begins Phase 1 Study for NMRA-898
18d ago
8K
NMRA
Neumora Therapeutics initiates Phase 1 clinical study of NMRA-988
PremiumThe FlyNeumora Therapeutics initiates Phase 1 clinical study of NMRA-988
18d ago
NMRA
Neumora Reports Positive Preclinical Results for NMRA-215
Premium
Company Announcements
Neumora Reports Positive Preclinical Results for NMRA-215
18d ago
8K
NMRA
Neumora Therapeutics’ NMRA-215 shows weight loss efficacy
Premium
The Fly
Neumora Therapeutics’ NMRA-215 shows weight loss efficacy
18d ago
NMRA
Neumora Therapeuticsto hold a virtual meeting
PremiumThe Fly
Neumora Therapeuticsto hold a virtual meeting
21d ago
NMRA
Apple initiated, Hershey upgraded: Wall Street’s top analyst calls
PremiumThe Fly
Apple initiated, Hershey upgraded: Wall Street’s top analyst calls
2M ago
KC
HPE
Neumora Therapeutics downgraded to Underweight from Neutral at JPMorgan
PremiumThe Fly
Neumora Therapeutics downgraded to Underweight from Neutral at JPMorgan
2M ago
NMRA
Neumora Therapeutics Faces Challenges as It Transitions to Full Public Company Compliance
PremiumCompany Announcements
Neumora Therapeutics Faces Challenges as It Transitions to Full Public Company Compliance
3M ago
NMRA
Neumora Therapeutics’ Earnings Call Highlights Promising Pipeline
PremiumCompany AnnouncementsNeumora Therapeutics’ Earnings Call Highlights Promising Pipeline
3M ago
NMRA
Neumora Therapeutics, Inc.: Promising Potential in Obesity Therapeutics with NMRA-215
Premium
Ratings
Neumora Therapeutics, Inc.: Promising Potential in Obesity Therapeutics with NMRA-215
3M ago
NMRA
Promising Developments and Pipeline Progress Drive Buy Rating for Neumora Therapeutics
Premium
Ratings
Promising Developments and Pipeline Progress Drive Buy Rating for Neumora Therapeutics
3M ago
NMRA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >